2m 2m 2m 2m 2m 2m 2m
INMED PHARMA (INM)
NASDAQ
$1.54+$0.02 (+1.58%)
Price as of Jun 03, 2026 6:16 PM EDT- $5.2MMarket Cap
- -54.22%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
INMED PHARMA (INM)
$1.54+$0.02 (+1.58%)
Annual
Quarterly
06/30/2025 | 06/30/2024 | 06/30/2023 | 06/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 4.9M +7.50% | 4.6M +11.18% | 4.1M +279.61% | 1.1M N/A | |
Cost of Revenue | 3.2M -7.46% | 3.5M +44.28% | 2.4M +343.97% | 545,889 N/A | |
Gross Profit | 1.7M +55.02% | 1.1M -21.53% | 1.4M +158.13% | 543,546 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -2.9M -24.20% | -3.8M +0.88% | -3.7M -48.75% | -7.3M +36.43% | |
Depreciation and Amortization Expense | 212,839 -3.08% | 219,600 +8.58% | 202,249 +8.94% | 185,657 +53.61% | |
Total Operating Expenses | 9.7M +3.83% | 9.3M -4.95% | 9.8M -45.07% | 17.8M +79.18% | |
Operating Profit | -8.2M +6.44% | -7.7M -3.35% | -7.9M -57.34% | -18.6M +82.30% | |
Interest Income | 155,882 -70.47% | 527,901 +7.20% | 492,440 +412.48% | 96,090 +499.93% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 155,882 -70.47% | 527,901 +7.20% | 492,440 +412.48% | 96,090 +499.93% | |
Total Nonoperating Income and Expense | N/A N/A | 527,901 +22.44% | 431,165 N/A | N/A N/A | |
Income before Taxes | -8.2M +6.44% | -7.7M -3.35% | -7.9M -57.34% | -18.6M +82.30% | |
Income Taxes | N/A N/A | 7,100 -45.80% | 13,100 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | 2.0M N/A | N/A N/A | |
Net Income | -8.2M +6.34% | -7.7M -3.42% | -7.9M -57.27% | -18.6M +82.30% | |
Net Income from Continuing Operations Applicable to Common | -8.2M +6.44% | -7.7M -3.35% | -7.9M -57.34% | -18.6M +82.30% | |
Basic EPS and Net Income | -8.36 +727.72% | -1.01 -68.92% | -3.25 -90.20% | -33.17 +2,082.24% | |
Diluted EPS and Net Income | -8.36 +727.72% | -1.01 -68.92% | -3.25 -90.20% | -33.17 +2,082.24% | |
Basic Weighted Average Shares | 975,985 -87.19% | 7.6M +211.26% | 2.4M +336.58% | 560,829 -91.65% | |
Diluted Weighted Average Shares | 975,985 -87.19% | 7.6M +211.26% | 2.4M +336.58% | 560,829 -91.65% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 11.1M +68.54% | 6.6M -26.27% | 8.9M +44.29% | 6.2M -16.11% | |
Short-Term Investments | 43,384 +0.74% | 43,064 -3.06% | 44,422 -0.85% | 44,804 -3.57% | |
Cash and Cash Equivalents and Short-Term Investments | 11.1M +68.10% | 6.6M -26.15% | 9.0M +43.96% | 6.2M -16.03% | |
Total Current Assets | 12.9M +48.08% | 8.7M -23.32% | 11.3M +18.07% | 9.6M +14.56% | |
Accumulated Depreciation | 1.3M -1.25% | 1.4M +46.47% | 925,321 +79.16% | 516,470 +132.02% | |
Property and Plant and Equipment and Net | 992,199 -20.62% | 1.2M N/A | N/A N/A | 904,252 +176.87% | |
Total Long-Term Assets | 100,000 0.00% | 100,000 -4.68% | 104,908 -40.61% | 176,637 +1,105.30% | |
Total Assets | 15.6M +31.78% | 11.8M -16.19% | 14.1M +10.31% | 12.8M +30.74% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 1.8M -6.70% | 2.0M -1.44% | 2.0M -39.73% | 3.3M +49.84% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 305,755 -52.59% | 644,865 +3,931.92% | 15,994 -95.89% | 389,498 +105.77% | |
Total Liabilities | 2.1M -18.00% | 2.6M +29.76% | 2.0M -45.63% | 3.7M +54.24% | |
Retained Earnings | -117.2M +7.48% | -109.1M +7.57% | -101.4M +8.50% | -93.5M +24.85% | |
Total Stockholders Equity | 13.4M +45.93% | 9.2M -23.85% | 12.1M +33.17% | 9.1M +23.07% | |
Total Shares Outstanding | 2.0M -77.55% | 8.9M +167.98% | 3.3M +411.50% | 650,667 -91.92% | |
Cash Flow | |||||
Cash from Operating Activities | -7.8M +11.18% | -7.0M -4.08% | -7.3M -53.26% | -15.6M +59.17% | |
Capital Expenditures | N/A N/A | 9,293 -94.19% | 160,014 +309.16% | 39,108 +2,167.13% | |
Cash from Investing Activities | N/A N/A | -9,293 -98.60% | -661,804 -1.66% | -672,999 +38,914.43% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 12.3M +163.66% | 4.7M -56.42% | 10.7M -29.13% | 15.1M +38.84% | |
Financials Ratio | |||||
Gross Margin | 34.53% +44.20% | 23.94% -42.16% | 41.40% -17.03% | 49.89% N/A | |
Operating Margin | -165.14% -0.99% | -166.79% -13.07% | -191.86% -88.76% | -1,707.32% N/A | |
Return on Assets | -59.57% +0.62% | -59.20% +0.17% | -59.10% -64.14% | -164.83% N/A | |
Return on Equity | -72.10% +0.02% | -72.08% -4.00% | -75.09% -66.78% | -226.07% N/A | |
Revenue Growth | 7.50% -32.87% | 11.18% -96.00% | 279.61% N/A | N/A N/A | |
Current Ratio | 6.99 +58.70% | 4.41 -22.20% | 5.66 +95.90% | 2.89 N/A | |
Cash Ratio | 6.02 +80.63% | 3.33 -25.19% | 4.45 +139.41% | 1.86 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow